Multi-strain Probiotic Supplement for Digestive Comfort and Well-being in Healthy Women

Inclusion Criteria: * Self-reported gas and/or bloating occurring on 4 or more days per week for at least the past 6 months * Mild-to-moderate ongoing gastrointestinal symptoms at screening, defined as a PROMIS Gastrointestinal Gas and Bloating Scale T-score of 55 to 69, inclusive * Body mass index (BMI) 18.5 to 32.5 kg/m2 (inclusive) * Self-reported symptoms of hormonal imbalance within the past 3 months, including at least one of the following: irregular or unpredictable menstrual cycles, acne, excess facial or body hair growth, or scalp hair thinning * If using psychotropic medication (including antidepressants, anxiolytics, mood stabilizers, or stimulants): stable medication and dose for at least three months prior to screening, with no anticipated changes during the study; medication name, dose, and start date recorded at screening * If using hormonal contraception: stable method for at least three months prior to screening, with no anticipated changes during the study; method and start date recorded at screening * Willing to abstain from all other probiotic and prebiotic supplements and probiotic-fortified functional foods from screening through study completion * Willing and able to maintain consistent diet, physical activity, and medication habits for the duration of the study * Willing and able to provide electronic informed consent and comply with the protocol * Resident of the United States with access to a smartphone with internet access and a functioning front-facing or rear camera, to allow completion of all online instruments and the skin health selfie assessment * Able to read and understand English at the 6th-grade level Exclusion Criteria: * Current use of a GLP-1 receptor agonist of any class or type, or use within the 3 months prior to screening * Use of any probiotic or prebiotic dietary supplement within the 4 weeks prior to screening * Use of systemic antibiotics within the 4 weeks prior to screening, or anticipated use during the study * Diagnosed gastrointestinal disease or disorder, including inflammatory bowel disease (Crohn's disease, ulcerative colitis), celiac disease, gastroparesis, gastrointestinal malignancy, or prior bariatric or other major gastrointestinal surgery * Current or past diagnosis of endometriosis or a thyroid or other endocrine/gynecological disorder, whether or not currently controlled * Chronic or serious medical conditions, including uncontrolled cardiovascular, metabolic, neurologic, immune (including immunocompromised states), renal, or hepatic disease, or any medical condition deemed exclusionary by the Principal Investigator * Current or past diagnosis of bipolar I/II disorder, schizophrenia spectrum or other psychotic disorder; psychiatric hospitalization, suicidal ideation, suicide attempt, or self-harm behavior in the past 12 months * Initiation, discontinuation, or dose change of any psychotropic medication within the 3 months prior to screening * Allergy or sensitivity to any ingredient in the study product * History of drug or alcohol abuse in the past 12 months * Currently pregnant, breastfeeding, or planning to become pregnant during the study period * Participation in another interventional research study within 30 days prior to screening that could confound the outcomes of this study * Currently in prison, in custody, or otherwise a ward of the state